Critical Outcome T (OTCMKTS:COTQF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Separately, ValuEngine cut shares of Critical Outcome T from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 5th.

Shares of Critical Outcome T (OTCMKTS:COTQF) traded down $0.09 on Wednesday, hitting $0.80. 15,000 shares of the company’s stock were exchanged, compared to its average volume of 1,510. Critical Outcome T has a 52 week low of $0.80 and a 52 week high of $4.80.

WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/critical-outcome-t-cotqf-upgraded-by-zacks-investment-research-to-hold.html.

About Critical Outcome T

Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The company’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.

Get a free copy of the Zacks research report on Critical Outcome T (COTQF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Critical Outcome T Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T and related companies with MarketBeat.com's FREE daily email newsletter.